MOUNTAIN VIEW, Calif., May 23 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Bob Korsan, Senior Scientist, will speak to members of the pharmaceutical and biotechnology industries via web conference on the collaborative and strategic benefits of using modeling and simulation to optimize a central nervous system (CNS) product franchise.
The web conference will be held on May 25, 2006, at 2:00 p.m. Eastern Daylight Time (7:00 p.m. GMT, 11:00 a.m. PDT). More information is available at http://www.pharsight.com/events/events_home.php .
Mr. Korsan’s presentation will discuss how model-based recommendations from early phase trial data (phase I and IIa) have been used to accelerate progression to confirmatory trials (phase III) and approval in multiple neurological indications for narcolepsy, obstructive sleep apnea, shift work sleep disorder, and attention deficit hyperactivity disorder.
“FDA’s Critical Path Initiative is pushing companies to modernize their drug development process by relying more on modeling and simulation,” said Shawn O’Connor, Pharsight president, CEO, and chairman. “These case examples illustrate how a major CNS biopharmaceutical company used modeling and simulation to win regulatory approval for treating a larger pool of patients, and how model-based approaches evolved to become a central input to the company’s lifecycle management strategy for this compound and its successors.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, allof EVC Group, for Pharsight Corporation
Web site: http://www.pharsight.com//
